

EXHIBIT 5

Christopher Thompson

January 6, 2006

Carson City, NV

1

UNITED STATES DISTRICT COURT

DISTRICT OF MASSACHUSETTS

IN RE PHARMACEUTICAL INDUSTRY AVERAGE) MDL NO. 1456

WHOLESALE PRICE LITIGATION) CIVIL ACTION:

-----) 01-CV-12257-PBS

THIS DOCUMENT RELATES TO STATE OF)

NEVADA V. ABBOTT LABORATORIES, Et al,)

Case No. 02-CV-00260 (Nevada I) and)

STATE OF NEVADA V. AMERICAN HOME)

PRODUCTS, et al., Case No.)

02-CV-12086-PBS (Nevada II))

DEPOSITION OF CHRISTOPHER THOMPSON

CARSON CITY, NEVADA

BE IT REMEMBERED that on Friday, the 6th day
of January, 2006, at the hour of 9:05 a.m., at the
offices of the Attorney General, 198 N. Carson Street,
Carson City, Nevada, before me, CINDY LEE BROWN, a
notary public, personally appeared CHRISTOPHER
THOMPSON, who was by me first duly sworn, and was
examined as a witness in said cause.

Henderson Legal Services
(202) 220-4158


Christopher Thompson

January 6, 2006

Carson City, NV

<p style="text-align: right;">58</p> <p>1 program?</p> <p>2 A. I don't recall anything as far as the cost</p> <p>3 of prescription drugs. Let me just backtrack on that</p> <p>4 as I say that. The one place where I do recall some</p> <p>5 concerns about prescription drugs and the cost of</p> <p>6 prescription drugs was regarding the cost for the</p> <p>7 mentally disabled. And I do recall some specific</p> <p>8 discussions both about the types of drugs that were</p> <p>9 included in the formularies and the cost for those</p> <p>10 drugs.</p> <p>11 Q. What, if any, cost-saving measures did the</p> <p>12 State consider while you were the director?</p> <p>13 MS. BRECKENRIDGE: Objection.</p> <p>14 THE WITNESS: Are you saying overall or as</p> <p>15 it relates to --</p> <p>16 BY MR. LITOW:</p> <p>17 Q. Did you consider, for example, using a</p> <p>18 preferred drug list for drugs or using a MAC pricing,</p> <p>19 M-A-C?</p> <p>20 A. During that time the primary focus was on</p> <p>21 moving people into managed care, and as a result,</p> <p>22 essentially, shifting out of the issues of direct</p>	<p style="text-align: right;">60</p> <p>1 Q. Any other agencies that you're aware of?</p> <p>2 A. I can't think of any others.</p> <p>3 Q. Did you ever have conversations with</p> <p>4 anybody from the Mental Health Division regarding the</p> <p>5 prices at which they were purchasing drugs?</p> <p>6 A. I may have. I don't have any specific</p> <p>7 recollection of them.</p> <p>8 Q. And do you know specifically who at that</p> <p>9 division you would have spoken to or who would have</p> <p>10 had knowledge of the prescription drug purchasing?</p> <p>11 A. It would have been, perhaps, Mike Torvenin,</p> <p>12 perhaps Carlos Brandenburg, who was the, Carlos was</p> <p>13 the administrator of the division. Mike at that time</p> <p>14 was the chief accountant.</p> <p>15 Q. Correct me if I'm wrong, but I believe you</p> <p>16 testified that your division fell under the scope of</p> <p>17 the Department of Human Resources; is that correct?</p> <p>18 A. That's correct.</p> <p>19 Q. Was the Mental Health Division also under</p> <p>20 the Department of Human Resources?</p> <p>21 A. Yes.</p> <p>22 Q. What sorts of communications did you have</p>
<p style="text-align: right;">59</p> <p>1 reimbursement of drug costs. I heard some</p> <p>2 discussions, and I don't recall, I don't recall</p> <p>3 specifically whether it was at a Medicaid directors</p> <p>4 conference or whether it was at an NGA meeting or</p> <p>5 whether it was at some other kind of national</p> <p>6 conference, some discussion about moving into</p> <p>7 preferred drug lists or that kind of management of</p> <p>8 prescription drugs.</p> <p>9 And at that time it was not something that</p> <p>10 I was going to spend our resources on. It was lower</p> <p>11 down, it was quite a bit lower down on the list.</p> <p>12 Q. When you were with the division, to your</p> <p>13 knowledge, were any other State agencies involved in</p> <p>14 purchasing prescription drugs?</p> <p>15 A. I believe that the -- okay. Let me try to</p> <p>16 get the name right. I -- what's the name of mental</p> <p>17 health and mental retardation now? I mean, it's</p> <p>18 developmental disability or something.</p> <p>19 Q. Whatever the division that was responsible</p> <p>20 for mental health services?</p> <p>21 A. Yeah. That group had their own dispensary,</p> <p>22 and so I'm aware that they were purchasing drugs.</p>	<p style="text-align: right;">61</p> <p>1 with drug manufacturers during your tenure at the</p> <p>2 division?</p> <p>3 A. The only -- and it wasn't directly with</p> <p>4 drug manufacturers, but with some of their lobbyists.</p> <p>5 I know that in the 1995 session and in the 1997</p> <p>6 session there was quite a bit of discussion</p> <p>7 regarding, regarding managed care, and from the</p> <p>8 pharmacies there was, there were issues of assuring</p> <p>9 that they would be included in whatever groups were</p> <p>10 allowed to work with those managed care companies.</p> <p>11 There was also some specific legislation at the time</p> <p>12 that they wanted to, essentially, to protect their</p> <p>13 position with those managed care organizations.</p> <p>14 Q. Did any other entities, other than Nevada</p> <p>15 Medicaid itself, make payments to providers in</p> <p>16 connection with the Medicaid program?</p> <p>17 MS. BRECKENRIDGE: Objection.</p> <p>18 THE WITNESS: Did anyone other than -- I'm</p> <p>19 not sure, I'm not sure what you mean by that.</p> <p>20 BY MR. LITOW:</p> <p>21 Q. Well, other than Nevada Medicaid itself,</p> <p>22 did Medicaid providers receive reimbursement from any</p>

EXHIBIT 6



**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

IN RE PHARMACEUTICAL INDUSTRY
AVERAGE WHOLESALE PRICE
LITIGATION

MDL No. 1456
CIVIL ACTION: 01-CV-12257-PBS
PBS

Judge Patti B. Saris
Chief Magistrate Judge Marianne B. Bowler

THIS DOCUMENT RELATES TO
State of Nevada v. Abbott Labs, Inc., et al.,
Case No. CV02-00260 (*Nevada I*)

*State of Nevada v. American Home Prods. Cop.,
et al.*, 02-CV-12086-PBS (*Nevada II*)

**SECOND NOTICE OF RULE 30(B)(6) DEPOSITION
TO PLAINTIFF THE STATE OF NEVADA**

PLEASE TAKE NOTICE that pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, Defendants in the above-captioned actions, by and through their counsel, will take the deposition upon oral examination of a representative or representatives designated by the State of Nevada (hereinafter "Plaintiff") to testify on behalf of Plaintiff concerning all matters described herein, before a Notary Public or other person authorized to administer oaths at 198 N. Carson Street, Carson City, NV, on February 22, 2006, at 10:00AM. The deposition will be recorded by stenographic and/or sound and visual means and will continue from day to day until completion.

Pursuant to Rule 30(b)(6), Plaintiff shall designate in writing to the undersigned counsel for Defendants one or more officers, officials, employees, or other representative to testify on their behalf who are most knowledgeable about and will testify as to matters

known or reasonably available to Plaintiff in regard to the matters set forth below.

Plaintiff is further requested to set forth the matter or matters on which each such designated person will testify.

All terms used in this Notice, whether or not capitalized, shall be defined as stated in Defendants' First Set of Interrogatories and Requests for Production to the State of Nevada and Defendants' First Set of Requests for Admission to the State of Nevada.

Unless otherwise specified, the relevant time period is the period from January 1991 to the present.

AREAS OF INQUIRY

Plaintiff is requested to designate one or more persons who consent to testify on its behalf concerning the following matters:

1. The formula or other basis on which each Subject Drug was purchased or reimbursed by Nevada's Public Employee Benefits Fund; negotiations with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.
2. The formula or other basis on which each Subject Drug was purchased or reimbursed by Nevada's Bureau of Prisons; negotiations with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.
3. The formula or other basis on which each Subject Drug was purchased or reimbursed by Nevada's Division of Child and Family Services; negotiations

with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.

4. The formula or other basis on which each Subject Drug was purchased or reimbursed by Nevada's Division of Mental Health and Developmental Services; negotiations with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.
5. The formula or other basis on which each Subject Drug was purchased or reimbursed by Nevada's Health Division; negotiations with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.
6. The formula or other basis on which each Subject Drug was purchased or reimbursed by Nevada's Senior Rx Program; negotiations with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.
7. Communications between Plaintiff and physicians, pharmacists, or other Medicaid providers, regarding changes to the rate of reimbursement for services provided under Medicaid.

8. Communications between Plaintiff and any pharmacy association regarding reimbursement or acquisition costs for pharmaceuticals or any Subject Drug.
9. Communications between Plaintiff and Myers & Stauffer or any other consultant or adviser regarding AWP or reimbursement or acquisition costs for pharmaceuticals or any Subject Drug.
10. Communications between Plaintiff and Ven-A-Care or any other complainant or “whistleblower,” or their attorneys or other representatives, regarding AWP or reimbursement or acquisition costs for pharmaceuticals or any Subject Drug.
11. Any efforts by Plaintiff to determine providers’ actual acquisition costs for pharmaceuticals or any Subject Drug.
12. Any consideration given by Plaintiff to the meaning of AWP or to defining that term for use in dealing with Plaintiff.
13. All efforts to obtain information from any Defendant(s) as to what providers were paying to acquire any Subject Drug.
14. Plaintiff’s compliance with its statutory and regulatory obligations to establish appropriate Medicaid reimbursement rates.
15. All efforts undertaken since Plaintiff began considering this litigation to determine the understanding of and reliance upon published AWP’s of the Subject Drugs by Nevada residents for whom Plaintiff is asserting damages pursuant to its alleged *parens patriae* powers.

16. All efforts undertaken since Plaintiff began considering this litigation to determine the damages, if any, suffered by Nevada residents for whom Plaintiff is asserting damages pursuant to its alleged *parens patriae* powers.
17. The steps taken by Plaintiff to preserve documents and information relating to this litigation since the filing of the complaint in this action.

Dated: January 31, 2006

/s/ Ronald G. Dove, Jr.
Ronald G. Dove, Jr.
Jason R. Litow
Covington & Burling
1201 Pennsylvania Avenue, NW
Washington, DC 20004
(202) 662-5685

*Attorneys for SmithKline Beecham
Corp., d/b/a GlaxoSmithKline on behalf
of Defendants in the above-captioned
actions.*

CERTIFICATE OF SERVICE

I hereby certify that I caused a true and correct copy of the foregoing Defendants' Second Notice of Rule 30(b)(6) Deposition to Plaintiff State of Nevada to be served on all counsel of record electronically via Lexis/Nexis File & Serve on January 31, 2006, pursuant to Case Management Order No. 2.

Dated: January 31, 2006

/s/ Jason R. Litow
Jason R. Litow

EXHIBIT 7



UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS

IN RE PHARMACEUTICAL INDUSTRY
AVERAGE WHOLESALE PRICE
LITIGATION

MDL No. 1456
CIVIL ACTION: 01-CV-12257-PBS
PBS

Judge Patti B. Saris
Chief Magistrate Judge Marianne B. Bowler

THIS DOCUMENT RELATES TO
State of Montana v. Abbott Labs, Inc., et al.,
D. Mont. Cause No. CV- 02-09-H-DWM

SECOND NOTICE OF RULE 30(B)(6) DEPOSITION
TO THE STATE OF MONTANA

PLEASE TAKE NOTICE that pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, Defendants in the above-captioned action, by and through their counsel, will take the deposition upon oral examination of a representative or representatives designated by the State of Montana (hereinafter "Plaintiff") to testify on behalf of Plaintiff concerning all matters described herein, before a Notary Public or other person authorized to administer oaths at the offices of Gough, Shanahan, Johnson & Waterman, 33 S. Last Chance Gulch, P.O. Box 1715, Helena, MT, 59601, on February 22, 2006, at 9:30am. The deposition will be recorded by stenographic and/or sound and visual means and will continue from day to day until completion.

Pursuant to Rule 30(b)(6), Plaintiff shall designate in writing to the undersigned counsel for Defendants one or more officers, officials, employees, or other representative to testify on their behalf who are most knowledgeable about and will testify as to matters

known or reasonably available to Plaintiff in regard to the matters set forth below.

Plaintiff is further requested to set forth the matter or matters on which each such designated person will testify.

All terms used in this Notice, whether or not capitalized, shall be defined as stated in Defendants' First Set of Interrogatories and Requests for Production to the State of Montana and Defendants' First Set of Requests for Admission to the State of Montana.

Unless otherwise specified, the relevant time period is the period from January 1991 to the present.

AREAS OF INQUIRY

Plaintiff is requested to designate one or more persons who consent to testify on its behalf concerning the following matters:

1. The formula or other basis on which each Subject Drug was purchased or reimbursed by Montana's State Employees Benefits Plan; negotiations with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.
2. The formula or other basis on which each Subject Drug was purchased or reimbursed by Montana's Department of Corrections; negotiations with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.
3. The formula or other basis on which each Subject Drug was purchased or reimbursed by Montana's State Workers' Compensation Fund; negotiations

with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.

4. The formula or other basis on which each Subject Drug was purchased or reimbursed by Montana's Addictive & Mental Disorders Division; negotiations with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.
5. The formula or other basis on which each Subject Drug was purchased or reimbursed by Montana's Children's Health Insurance Program Special Health Bureau; negotiations with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.
6. The formula or other basis on which each Subject Drug was purchased or reimbursed by Montana's End-Stage Renal Disease Program; negotiations with distributors, PBMs, or other vendors or representatives for purchasing each Subject Drug; and, if no formula was involved, the actual purchase or reimbursement price for each Subject Drug.
7. Communications between Plaintiff and physicians, pharmacists, or other Medicaid providers, regarding changes to the rate of reimbursement for services provided under Medicaid.

8. Communications between Plaintiff and the Montana Pharmacy Association regarding reimbursement or acquisition costs for pharmaceuticals or any Subject Drug.
9. Communications between Plaintiff and Time Stratton or any other consultant or adviser regarding AWP or reimbursement or acquisition costs for pharmaceuticals or any Subject Drug.
10. Communications between Plaintiff and Ven-A-Care or any other complainant or “whistleblower,” or their attorneys or other representatives, regarding AWP or reimbursement or acquisition costs for pharmaceuticals or any Subject Drug.
11. Any efforts by Plaintiff to determine providers’ actual acquisition costs for pharmaceuticals or any Subject Drug.
12. Any consideration given by Plaintiff to the meaning of AWP or to defining that term for use in dealing with Plaintiff.
13. All efforts to obtain information from any Defendant(s) as to what providers were paying to acquire any Subject Drug.
14. Plaintiff’s use of Direct Price as a basis for reimbursement under its Medicaid program for any of the Subject Drugs.
15. Plaintiff’s compliance with its statutory and regulatory obligations to establish appropriate Medicaid reimbursement rates.
16. All efforts undertaken since Plaintiff began considering this litigation to determine the understanding of and reliance upon published AWP’s of the

Subject Drugs by Montana residents for whom Plaintiff is asserting damages pursuant to its alleged *parens patriae* powers.

17. All efforts undertaken since Plaintiff began considering this litigation to determine the damages, if any, suffered by Montana residents for whom Plaintiff is asserting damages pursuant to its alleged *parens patriae* powers.
18. The steps taken by Plaintiff to preserve documents and information relating to this litigation since the filing of the complaint in this action.

Dated: January 31, 2006
Philadelphia, PA

/s/ Erica Smith-Klocek
John C. Dodds
Erica Smith-Klocek
MORGAN, LEWIS & BOCKIUS LLP
1701 Market Street
Philadelphia, PA 19103

*Attorneys for Pfizer Inc. and Pharmacia
Corporation on behalf of Defendants in
the above-captioned action.*

CERTIFICATE OF SERVICE

I hereby certify that I caused a true and correct copy of the foregoing Defendants' Second Notice of Rule 30(b)(6) Deposition to Plaintiff State of Montana to be served on all counsel of record electronically via Lexis/Nexis File & Serve on January 31, 2006, pursuant to Case Management Order No. 2.

Dated: January 31, 2006
Philadelphia, PA

/s/ Erica Smith-Klocek
Erica Smith-Klocek

EXHIBIT 8

Jeff Buska

October 19, 2005

Helena, MT

Page 1

THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS

---oOo---

In re: PHARMACEUTICAL,	MDL DOCKET NO.
INDUSTRY AVERAGE WHOLESALE	CIVIL ACTION
PRICE LITIGATION	01CV12257-PBS

THIS DOCUMENT RELATES TO:
ALL ACTIONS

Volume I
DEPOSITION OF JEFF BUSKA
Taken at:
Law offices of
Gough, Shanahan, Johnson & Waterman
33 South Last Chance Gulch
Helena, Montana
October 19, 2005
9:00 a.m.

Henderson Legal Services
(202) 220-4158

6d2a050c-6de1-47d1-a56c-f87396199dd2

Jeff Buska

October 19, 2005

Helena, MT

Page 86

1 Q. Who coordinated the meetings prior to Ms.
2 Bernard?

3 A. It would be under Maggie Bullock and Nancy
4 Ellery and their administrative staff.

5 Q. Have you heard of the Montana Medical Care
6 Advisory Council?

7 A. I believe that was the name of the Health
8 Coalition prior to the redesign. That's what they
9 called it prior.

10 Q. The redesign you're referring to there was
11 this Healthcare Redesign Advisory Council?

12 A. That would be correct.

13 Q. I want to ask you about a few non-Medicaid
14 entities. The reason I want to ask is the complaint
15 in this case suggests that numerous state agencies
16 overpaid for prescription drugs because of the alleged
17 inflation of AWP. I'm trying to figure out which
18 other agencies those are.

19 A. Okay. The other agencies that, to my
20 knowledge, pay for prescription drugs would be the
21 state, the State Employees Benefits Plan, and that is
22 operated through the Department of the Administration;

Henderson Legal Services
(202) 220-4158

6d2a050c-6de1-47d1-a56c-f87396199dd2

Jeff Buska

October 19, 2005

Helena, MT

Page 87

1 our Department of Corrections pays for prescription
2 drugs; our State Fund, state workers' compensation. I
3 believe I mentioned a couple of them earlier that are
4 non-Medicaid.

5 Q. You mentioned the children's division?

6 A. Children's special health services and the
7 end-stage renal disease program.

8 Q. Are you aware of any other state agencies
9 that purchase drugs from manufacturers?

10 A. Those are the only ones that I'm aware of.

11 Q. You wouldn't be aware of the state
12 procurement bureau purchasing prescription drugs?

13 A. That is part of the Department of
14 Administration for the State Employees Benefits Plan.

15 Q. What about any higher education
16 institutions such as the University of Montana? Do
17 they purchase prescription drugs?

18 A. It is possible that they do. I'm not sure
19 if they are part of the State Employees Benefits
20 Program or if it's a separate entity.

21 Q. Do you know whether the agencies you just
22 mentioned that purchase drugs from manufacturers, do

Henderson Legal Services
(202) 220-4158

Jeff Buska

October 19, 2005

Helena, MT

Page 88

1 you know whether they purchase them directly from the
2 manufacturers?

3 A. No, I don't know if they purchase them
4 directly or not.

5 Q. And by "indirectly", I'm referring to
6 wholesalers. You don't know whether they purchase
7 them from wholesalers?

8 A. No, I don't. I'm not aware of their
9 business practices. I'm aware of the typical business
10 practice in the administration of pharmaceuticals,
11 which is through pharmacy benefits managers.

12 Q. Through PBMs.

13 A. That is correct.

14 Q. So you know that's typical, but you don't
15 know one way or the other what these agencies do?

16 A. How they do it, no, I do not.

17 Q. Do you know whether they participate in
18 any group purchasing organizations to buy drugs?

19 A. I'm aware that the Department of
20 Corrections is involved with the Department of Public
21 Health in a group purchasing arrangement. At least
22 they used to be. They're not in it currently.

Henderson Legal Services
(202) 220-4158

6d2a050c-6de1-47d1-a56c-f87396199dd2

Jeff Buska

October 19, 2005

Helena, MT

Page 89

1 Q. They are not?

2 A. They are not.

3 Q. Do you know for how many years they had
4 some type of joint purchasing arrangement?

5 A. I'm not aware of the time period of that,
6 the exact time period.

7 Q. Since you don't know exactly how these
8 agencies purchase prescription drugs, is it fair to
9 say you don't know whether they negotiate or contract
10 for their prices?

11 A. Can you explain that in terms of "contract
12 for their prices"?

13 Q. I think that's a poorly worded question.
14 You're not aware -- are you aware of the contractual
15 arrangements between these state agencies and the drug
16 manufacturers?

17 A. No, I'm not aware of their contracts.

18 Q. Are you aware of any state agencies that
19 don't purchase drugs but may reimburse for
20 prescription drugs, such as possibly the Department of
21 Labor and Industry?

22 A. I don't know.

Henderson Legal Services
(202) 220-4158

6d2a050c-6de1-47d1-a56c-f87396199dd2

Jeff Buska

October 19, 2005

Helena, MT

Page 90

1 Q. Do you know whether Montana Medicaid ever
2 compared the prices at which they were purchasing
3 drugs with the prices paid by the other state
4 entities?

5 A. No.

6 Q. Just to clarify, you don't know one way or
7 the other?

8 A. I don't know one way or the other.

9 Q. Did you ever speak about prescription drug
10 pricing with anyone at other Montana agencies?

11 A. No.

12 Q. Are there any management overlaps between
13 the Department of Public Health and Human Services and
14 the other state agencies that you mentioned that
15 purchase drugs from manufacturers?

16 A. Management overlap? No, I don't believe
17 so.

18 Q. Are you aware of any employees who have
19 moved between DPHHS and any of those other public
20 entities that purchase prescription drugs?

21 A. I don't recall any staff that have moved
22 from one to the other.

Henderson Legal Services
(202) 220-4158

6d2a050c-6de1-47d1-a56c-f87396199dd2

Jeff Buska

October 19, 2005

Helena, MT

Page 91

1 Q. Are you aware of any mechanism for sharing
2 information about drug purchasing across Montana
3 agencies?

4 A. For sharing the information, if I
5 understand your question correctly, of sharing
6 information about how we paid for the prescription
7 drugs?

8 Q. The prices that are paid or the
9 reimbursement for those drugs.

10 A. I'm not aware. Of course, our
11 reimbursement is public knowledge for the Medicaid
12 program. They have access to that. They may have
13 looked it up.

14 Q. Is it public knowledge of the pricing for
15 the other state agencies who purchase drugs from
16 manufacturers?

17 A. Probably. Under the Freedom of
18 Information Act, I would imagine it's probably public
19 knowledge how they pay for it.

20 Q. So when you say that you've never spoken
21 about prescription drug pricing with anyone at any
22 other Montana agencies, is it also fair to say you

Henderson Legal Services
(202) 220-4158

6d2a050c-6de1-47d1-a56c-f87396199dd2

Jeff Buska

October 19, 2005

Helena, MT

Page 92

1 never participated in any meetings with
2 representatives from other Montana agencies about
3 prescription drug pricing?

4 A. I don't recall any specific discussions
5 with other agencies.

6 Q. Or any task forces, joint task forces?

7 A. No, not that I'm aware of, not that I have
8 been personally involved with.

9 Q. Who would have the most knowledge on the
10 issue of drug purchases by Montana agencies other than
11 Medicaid?

12 A. Probably the bureau chief of the
13 department of the administration for the employee
14 benefits bureau would have knowledge of how they do
15 it. I believe her name is Connie Welch. The State
16 Fund, I don't know the name of the person, but I'd
17 contact the executive director of that fund.

18 Q. That was the employee benefits fund?

19 A. The State Fund, I think is what it's
20 referred to, the workers' compensation. The employee
21 benefits would be Connie Welch.

22 Q. Who within the Department of Corrections

Jeff Buska

October 19, 2005

Helena, MT

Page 93

1 would be most knowledgeable about the purchasing of
2 drugs from manufacturers?

3 A. Probably the director is where you would
4 start with.

5 Q. Who is that?

6 A. I don't know his name. I think it's Bud
7 Clinch, but I'm not sure if that's the right person or
8 not.

9 (Document marked Deposition
10 Exhibit Buska 005 for identification.)

11 BY MS. O'SULLIVAN:

12 Q. Mr. Buska, I'm showing you what has been
13 marked as Exhibit Buska 005, which is Defendants' First
14 Set of Interrogatories and Requests for Production to
15 the State of Montana. Have you seen this before?

16 A. Yes, I believe it looks familiar.

17 MS. BRECKENRIDGE: You might have seen it
18 in a different format.

19 Q. (By Ms. O'Sullivan) Do you recall when you
20 saw it?

21 A. I believe this is the document that
22 requested the agency to put together documents and

Henderson Legal Services
(202) 220-4158

6d2a050c-6de1-47d1-a56c-f87396199dd2

EXHIBIT 9

